# Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

> **NCT03219671** · PHASE2 · UNKNOWN · sponsor: **Alona Zer** · enrollment: 20 (estimated)

## Conditions studied

- Classic Kaposi Sarcoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03219671
- **Lead sponsor:** Alona Zer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219671, "Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03219671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*